At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 17, 2026 at 15:00 ET
Zymeworks announced six preclinical poster presentations at AACR 2026 showcasing its next-generation antibody-drug conjugate (ADC) programs, including first-in-class pan-RAS inhibitor ADCs targeting solid tumors. New data highlight efficacy, tumor-selective delivery, and favorable tolerability across multiple programs. An oral presentation on Phase 1 data for ZW191 will follow on April 21.
- Six poster presentations at AACR 2026 feature preclinical data from Zymeworks' ADC and payload development programs.
- Programs include first-in-class pan-RAS inhibitor ADCs targeting Ly6E, CLDN18.2, PTK7, and FRα.
- ZW191 Phase 1 clinical data to be presented orally on April 21, 2026, from the first-in-human trial in advanced solid tumors.
- Preclinical data show strong anti-tumor activity at low doses (as low as 1 mg/kg), favorable tolerability, and potential for combination therapy.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access